Tammy Hawkins
Psychiatric/Mental Health · Jonesboro, ARNPI 1215212089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,607 and has fallen 62.8% since, to $971 in 2025. Among psychiatric/mental health clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$972
- Neurocrine Biosciences, Inc.$810
- Otsuka America Pharmaceutical, Inc.$708
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$682
- Axsome Therapeutics, Inc.$608
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $1,748 |
| Johnson & Johnson | 46 | $972 |
| Neurocrine Biosciences, Inc. | 59 | $810 |
| Otsuka America Pharmaceutical, Inc. | 36 | $708 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $682 |
| Axsome Therapeutics, Inc. | 17 | $608 |
| Lundbeck LLC | 25 | $425 |
| Supernus Pharmaceuticals, Inc. | 16 | $285 |
| Sunovion Pharmaceuticals Inc. | 26 | $280 |
| Alkermes, Inc. | 12 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $236 |
| Tris Pharma Inc | 12 | $211 |
| Idorsia Pharmaceuticals US Inc | 6 | $82 |
| Novartis | 3 | $50 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| Corium, LLC | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Procept Biorobotics Corporation | 1 | $42 |
| Abiomed | 1 | $38 |
| Pacira Pharmaceuticals Incorporated | 1 | $35 |
| Bausch Health US, LLC | 2 | $35 |
| Boston Scientific | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $14 |
How this compares
$7,733 in reported general payments places this provider in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $106,991 |
| IngrezzaValbenazine Tosylate | 12 | $100,577 |
| VraylarCariprazine Hcl | 57 | $78,174 |
| RexultiBrexpiprazole | 76 | $61,623 |
| AuvelityDextromethorphan Hbr/Bupropion | 39 | $33,998 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,404 |
| FetzimaLevomilnacipran Hcl | 12 | $5,885 |
| Duloxetine Hcl | 110 | $3,795 |
| Mirtazapine | 141 | $3,348 |
| Vilazodone Hcl | 32 | $2,900 |
| Memantine Hcl | 35 | $2,641 |
| Divalproex Sodium | 34 | $1,708 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 72 | $1,667 |
| Tiagabine Hcl | 13 | $1,537 |
| Lamotrigine | 153 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $972 | $106,99134 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $810 | $100,57712 claims |
| AbbVieVraylar, Fetzima | $1,748 | $84,05969 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $708 | $61,62376 claims |
| Axsome Therapeutics, Inc.Auvelity | $608 | $33,99839 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $236 | $11,40423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Jonesboro
- Stacey LynchJonesboro$6K
- Kimberly StottsJonesboro$5K
- Keiah HuntJonesboro$4K
- Kellie CoxJonesboro$4K
- Ottysha WhiteJonesboro$3K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.